title: [Skin manifestations of new targeted treatments].
abstract: Many cutaneous adverse events have been identified with recently developed targeted treatments. Some of them are common and specific, like paradoxical psoriasiform eruptions with anti-TNFα, papulopustular eruptions and paronychias with EGFR inhibitors and peculiar hand-foot skin reactions with multitargeted kinase inhibitors sorefenib and sunitinib. Patients treated with these recently available biologics need a careful monitoring.
authors.affiliation: Service de médecine interne, CHU Hôtel-Dieu, Nantes, France. muriel.hello@chu-nantes.fr
authors.forename: M
authors.initials: M
authors.lastname: Hello
authors.forename: S
authors.initials: S
authors.lastname: Barbarot
authors.forename: J
authors.initials: J
authors.lastname: Connault
mesh_terms: D003875:Drug Eruptions / Q000209:etiology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D014409:Tumor Necrosis Factor-alpha; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases